STEPUPIORS PI from FRCB-IDIBAPS Dr Sergi Castellvi-Bel shared expert insights about the significant progress made in identifying novel biomarkers for colorectal cancer within and beyond the inspiring and productive TRANSCOLONCAN COST Action he chaired.
Dr Castellvi-Bel outlined that TRANSCOLONCAN aimed at improving colorectal cancer screening, early detection, and monitoring by using liquid-biopsy approaches and better tumour profiling. The network also explored the use of CRISPR-Cas9 and immunotherapy to develop new treatments for the disease. He highlighted that over the past four years, several objectives were accomplished, including both scientific achievements and involvement of COST Inclusiveness Target Countries (ITC), young, and female researchers. The publication of the results of the genome-wide association studies from the EU and USA consortia was a significant milestone. Additionally, Milena Cavic, a young researcher from Serbia, received a Horizon Europe Twinning project STEPUPIORS, which was also a noteworthy achievement.
For more information, please read the full interview:
